Picroside: A Comprehensive Encyclopedic Reference
1. Identity and Natural Source
1.1 Botanical Origin and Taxonomy
Picrosides are a group of bioactive iridoid glycosides derived primarily from Picrorhiza kurroa Royle ex Benth., a small, perennial herb native to the alpine Himalayan mountain range. Picrorhiza kurroa Royle ex Benth. (Scrophulariaceae) is a fast-depleting, high-value medicinal plant endemic to alpine Himalayan mountains, distributed across elevations from 2,700 to 5,000 metres above sea level, ranging from Kashmir to Sikkim. The species is now classified as a member of the Plantaginaceae family and is a small perennial herb found mainly in the northwest Himalayan region, from Kashmir to Kumaun. It grows at elevations of 3,000–5,000 m, having a long, creeping rootstock that is bitter in taste, and preferably grows in rock crevices and moist sandy soil.
Known as kutki or कुटकी in Nepali, it is a perennial herb and is used as a substitute for Indian gentian (Gentiana kurroo). In Sanskrit, it is referred to as Katuka, Katuki, or Katu Rohini. The word "Picrorhiza" is derived from Greek — "picros" means bitter and "rhiza" means root — so the name translates literally as "bitter root."
A related species, Picrorhiza scrophulariiflora Pennell (also known as Neopicrorhiza scrophulariiflora), is found in China and Tibet and is the primary source of picrosides used in traditional Chinese medicine under the name Picrorhizae rhizoma (Hu huang lian). Picroside II is the active constituent extracted from Picrorhiza scrophulariiflora Pennell. The two species share a similar phytochemical profile of picrosides, and their rhizomes are used interchangeably in Chinese and Ayurvedic contexts.
The species has become endangered to near extinction due to unregulated collection from the wild, slower plant growth, and ecological destruction of natural habitats. There is a severe shortage of plant material while market demand is ever increasing. Kutki is listed in Appendix II of the Convention on International Trade in Endangered Species of Wild Fauna and Flora (CITES).
1.2 Chemical Identity: Picroside I and Picroside II
Picrosides are monoterpenoids with an iridoid backbone and a glycoside moiety. They are classified as Picroside I (P-I) and Picroside II (P-II) based on their functional group moieties: P-I has a cinnamate moiety and P-II has a vanillate moiety.
Picroside I is chemically designated as 6'-O-cinnamoylcatalpol and carries the CAS number 27409-30-9, with the molecular formula C24H28O11. Picroside I's synonym is 6'-Cinnamoylcatalpol. Picroside II (kutkoside) carries CAS number 39012-20-9 and the molecular formula C23H28O13 (molecular weight 512). Picroside II has the molecular formula C23H28O13 with a molecular weight of 512.
A crystalline compound called kutkin has been isolated from the roots and rhizomes of P. kurroa. It exists as a mixture of C9-iridoid glycosides — picroside I and picroside II — in the ratio of approximately 1:2. Among the isolated phytochemicals, picroside I and II are regarded as the marker compounds of this plant.
Beyond these two primary compounds, P. kurroa contains a wider array of iridoid and phenolic glycosides. P. kurroa contains as many as 7 iridoid glycosides, namely kutkin, kutkoside, picroside V, pikuroside, mussaenosidic acid, bartsioside, and boschnaloside. LC–ESI–MS/MS identification has confirmed the presence of iridoid glucosides such as picroside I, picroside II, picroside III, picroside IV, kutkoside, and pikuroside, as well as flavonoids like apocynin and vanillic acid. The plant also contains cucurbitacin, acetophenones, aliphatic homocyclic compounds, and triterpenoids.
It is a glycoside-rich plant that contains different classes of glycosides including iridoid-glycosides, phenolic glycosides, and cucurbitacin glycosides.
1.3 Organ-Specific Distribution and Biosynthesis
Picroside I is biosynthesized in the shoots and picroside II in the roots or stolons, whereas both ultimately accumulate in the rhizomes. Biosynthesis of picrosides occurs through a combined biosynthetic route involving non-mevalonate (MEP), mevalonate (MVA), phenylpropanoid, and iridoid pathways. The iridoid backbone is derived from geranyl pyrophosphate (GPP), which is synthesized by head-to-tail condensation of isopentenyl pyrophosphate (IPP) and its allelic isomer dimethylallyl diphosphate (DMAPP) via the cytosolic mevalonate and/or plastidic non-mevalonate pathway. The functional ester groups distinguishing the two picrosides — cinnamate for P-I and vanillate for P-II — are both derived from the phenylpropanoid pathway. Picroside II is biosynthesized via degradation of ferulic acid (FA) to produce vanillic acid (VA), which acts as its immediate biosynthetic precursor.
1.4 Common Forms and Preparations
The principal pharmacological fraction used in research and commerce is Picroliv (also spelled Picroliv or Kutkin), a standardised extract. Picroliv is obtained from 3–4 year-old roots and rhizomes of Picrorhiza kurroa and is an iridoid glycoside mixture containing 60% picroside I and kutkoside in the ratio of 1:1.5. Commercially, many P. kurroa-based hepato-stimulatory Ayurvedic drug brands use different proportions of P-I and P-II.
Available commercial forms include:
- Crude powdered rhizome/root: The dried, ground underground parts, used in traditional Ayurvedic formulations and capsules.
- Standardised hydroalcoholic extracts: Liquid or dry extracts standardised to a stated percentage of total picrosides (picroside I + picroside II), typically verified by HPLC.
- Picroliv / Kutkin fraction: A semi-purified iridoid glycoside fraction standardised for the 1:1.5 ratio of picroside I to kutkoside (picroside II), used extensively in Indian herbal drug formulations.
- Isolated pure picroside I or picroside II: Used exclusively in pharmaceutical research; not a standard consumer product.
2. Traditional and Historical Use
2.1 Ayurvedic Medicine (India)
Picrorhiza kurroa, known as Kutki, is an important medicinal plant traditionally recommended and used in Ayurveda for millennia. The rhizome has a long history of use in Indian Ayurvedic medicine for the treatment of digestive problems. The Ayurvedic textual tradition references kutki under various Sanskrit names including Katuka, Katurohini, and Tikta. Sushruta Samhita mentioned this herb in Mustadi Gana and Pipplayadi Gana, and katuki is also explained in various other ancient books like Bhavaprakash Nighantu, Nighantu Adarsha, Ashtang Samgraha, and Rajnighantu.
The traditional Ayurvedic uses are well-documented and multifaceted:
- It was traditionally used in Ayurveda as a bitter tonic to help stimulate appetite and aid digestion (stomachic).
- It was traditionally used in Ayurveda as a hepatoprotectant/liver protectant.
- It was traditionally used in Ayurveda as a laxative for the relief of occasional constipation.
- Other traditional uses include treatment of scorpion stings, asthma, liver diseases, and febrile infections.
- It has been traditionally used to treat disorders of the liver, upper respiratory tract diseases, fevers, dyspepsia, chronic diarrhoea, and scorpion stings.
- It has been used to treat jaundice caused by infectious hepatitis, including jaundice linked to infectious hepatitis.
In Ayurveda's constitutional framework, kutki is described as having a tikta rasa (bitter taste) and is considered to have Kapha-Pitta Shamaka effects — that is, it pacifies excess Kapha (phlegm-related) and Pitta (heat/bile-related) doshas. It is valued for its Tikta Rasa and Kapha-Pitta Shamaka effects, and is used in formulations like Ayush-64, addressing liver disorders, respiratory issues, and chronic metabolic disorders.
The leaf, bark, and underground parts of the plant — mainly rhizomes — are widely used in traditional medicine to treat indigestion problems due to improper digestion.
2.2 Tibetan and Chinese Traditional Medicine
Picrorhizae rhizoma (the dried rhizome of Picrorhiza kurroa) is a famous Chinese herb that has been traditionally used in China. In Traditional Chinese Medicine (TCM), Picrorhiza scrophulariiflora — the closely related Tibetan and Chinese species — is used in virtually identical applications to the Ayurvedic tradition, particularly for liver-related ailments and febrile conditions.
Picroside II isolated from Pseudolysimachion rotundum var. subintegrum has been used as traditional medicine to treat inflammatory diseases. This illustrates that picroside-containing plants across Asia have been ethnobotanically converged upon for similar therapeutic purposes.
2.3 Traditional Preparation Methods
Historically, the rhizome was prepared as a bitter decoction, powder, or infusion. The bitter taste — the very character that lent the plant its Ayurvedic classification as tikta rasa — was associated with cleansing, detoxifying, and digestive-stimulating properties.
3. Key Constituents and Active Compounds
3.1 Picroside I
Picroside I (6'-Cinnamoylcatalpol), an iridoid glycoside, is a hepatoprotective agent reported to be antimicrobial and used against hepatitis B. Picroside I has a cinnamate moiety esterified onto a catalpol backbone. Its molecular formula is C24H28O11. Iridoid glycosides picroside I and kutkoside have been found to stimulate the cell-mediated and humoral components of the immune system and improve the phagocytic function of the reticuloendothelial system.
3.2 Picroside II (Kutkoside)
Picroside II (PII), a glycoside derivative, is the main bioactive constituent of Picrorhiza kurroa. Picroside II, from the herb Picrorhiza scrophulariiflora Pennell, has antioxidant and anti-inflammatory activities. Previous studies have shown that picroside II has a wide range of pharmacological effects, including neuroprotective, hepatoprotective, antioxidant, and anti-inflammatory activities. It is the more extensively studied of the two primary picrosides, with a particularly large body of preclinical literature on cerebral ischemia, liver disease, and inflammation.
3.3 Kutkin (Picroliv)
Kutkin is a bitter glycoside which contains two C-9 iridoid glycosides, picroside I and kutkoside. A deviation from standard rules in modern medicines — where, instead of a single isolated fraction, a group of naturally occurring components exerts the desired therapeutic effect — was noted in the case of Picroliv or Kutkin of Picrorhiza kurroa.
3.4 Other Biologically Relevant Compounds
Other chemical compounds present in P. kurroa include d-mannitol, kutkiol, kutkisterol, and a ketone identical with apocynin. Apocynin (acetovanillone) is itself a well-studied NADPH oxidase inhibitor with anti-inflammatory properties. Picrorhizoside A, picrorhizoside B, picrorhizoside C, (−)-shikimic acid, ellagic acid, and isocorilagin have been found to inhibit cyclooxygenase-1 and 2 (COX-1 and COX-2) at 100 μg/ml. Picrorhiza acid is also known to inhibit COX-2 (responsible for inflammation and pain) at 100 μg/ml.
4. Mechanisms of Action
4.1 Hepatoprotective Mechanisms
The hepatoprotective activity of picrosides is multifactorial. Picroside II can evidently relieve hepatocyte injuries, help scavenge free radicals, protect normal constructions of the mitochondrial membrane, and enhance the activity of ATPase in mitochondria, thereby modulating the balance of liver energy metabolism — mechanisms that may underlie the hepatoprotective effects of picroside II.
Picroside II attenuated free fatty acid (FFA) accumulation in HepG2 cells by downregulation of FATP5, SREBP-1, and SCD, hence decreasing fatty acid uptake and lipid synthesis. Picroside II also decreases the production of reactive oxygen species (ROS) and increases the levels of antioxidants, including glutathione, manganese superoxide dismutase (MnSOD), and catalase.
Picroside II attenuates hepatic lipid accumulation in HepG2 cells by decreasing FFA uptake through FATP5, lipid synthesis via SREBP-1, and SCD. Further, hepatic gluconeogenesis was downregulated with a decrease in the expression of FOXO1 and PEPCK.
By reducing intracellular production of inflammatory chemokines and reactive oxygen species, picroside II inhibited the activation of hepatic stellate cells and reduced the deposition of extracellular matrix.
Picroliv has shown efficacy comparable to silymarin in rodent models of galactosamine, paracetamol, thioacetamide, and CCl4-induced hepatic damage. Picroliv has also shown a choleretic effect in rats and an anti-cholestatic effect in rats, guinea pigs, and cats treated with paracetamol and ethinyl estradiol.
4.2 Antioxidant Mechanisms
Suppression of superoxide anion generation in enzymatic, non-enzymatic, and metal ion chelator systems, and decrease in lipid peroxidation, are suggested as mechanisms of picrosides protecting cells against oxidative stress.
P. kurroa exhibits DPPH radical scavenging and metal chelating activities with IC50 values of 75.16 ± 3.2 and 55.5 ± 4.8 μg/mL, respectively, and also shows potent reducing power and total antioxidant activities.
4.3 Anti-inflammatory Mechanisms
Accumulating evidence has validated that picroside II exerts significant anti-inflammatory effects in the prevention and treatment of various systemic diseases. Picroside II has excellent immunomodulatory effects, which can alleviate inflammatory damage in various diseases by regulating immune cell differentiation, activating inflammatory signaling pathways, and secreting inflammatory factors.
Key anti-inflammatory targets documented in preclinical studies include:
- Picroside II can inhibit the expression of inflammatory factors such as Toll-like receptor 4 (TLR4), nuclear factor κB (NF-κB), caspase-3, and tumor necrosis factor α (TNF-α) in cerebral ischemic penumbra after middle cerebral artery occlusion and reperfusion.
- The inhibitory effect of picroside II on serum amyloid A (SAA)-induced IL-33 is mediated by suppressing the mitogen-activated protein kinase (MAPK) p38, ERK1/2, and NF-κB pathways.
- Hyaluronidase inhibitory activity has also been documented for picrosides I and IV, of relevance to anti-allergic mechanisms.
4.4 Neuroprotective Mechanisms
Multiple signalling pathways have been identified through which picroside II exerts neuroprotection in preclinical models of cerebral ischemia/reperfusion injury:
- Picroside II can down-regulate the expressions of TLR4, NF-κB, and TNF-α to inhibit apoptosis and inflammation induced by cerebral ischemic reperfusion injury and improve the neurobehavioral function of rats.
- Activation of ERK1/2 in cerebral ischaemia induces neuronal apoptosis, and picroside II may reduce neuronal apoptosis and confer protection against cerebral ischemic injury by inhibiting ERK1/2 activation.
- Previous studies have shown that picroside II has good antioxidant capacity to protect the blood-brain barrier (BBB) and can improve the neurological function of rats, thus potentially reducing the death rate from stroke.
4.5 Immunomodulatory Mechanisms
A glycoside fraction from P. kurroa roots has been shown to augment the bronchodilatory effect of isoprenaline and adrenaline, rendering guinea pigs less sensitive to histamine. It reduces histamine content of lung tissues and inhibits immunological release of histamine and the slow-reacting substance of anaphylaxis (SRS-A) from chopped lungs.
In the context of allergic asthma, in an HDM-induced asthmatic mouse model, picroside II significantly reduced inflammatory cell counts in the bronchoalveolar lavage fluid (BALF), the levels of total IgE and HDM-specific IgE and IgG1 in serum, airway inflammation, and mucus hypersecretion. ELISA analysis showed that picroside II down-regulated Th2-related cytokines (including IL-4, IL-5, and IL-13) and asthma-related mediators, while up-regulating the Th1-related cytokine IFN-γ in BALF. Picroside II also inhibited the expression of Th2-type cytokine genes and the transcription factor GATA3 in lung tissues.
Picroside II, but not dexamethasone, effectively inhibited SAA-induced IL-33 expression and secretion. The inhibitory effect was mediated by suppressing the MAPK p38, ERK1/2, and NF-κB pathways. This suggests that picroside II negatively modulates the SAA-IL-33 axis implicated in steroid-resistant lung inflammation.
5. Scientific Evidence by Area of Use
5.1 Liver Disease and Hepatoprotection
Animal and In Vitro Evidence
The hepatoprotective evidence for picrosides is most extensive at the preclinical level. Oral administration of Picroliv (12 mg/kg/day for 7 days), a standardised iridoid glycoside fraction of Picrorhiza kurroa, significantly prevented biochemical changes in liver and serum of galactosamine-toxicated rats. Oral administration of Picroliv (12 mg/kg/day for 7 days) significantly prevented the biochemical changes in liver and serum of galactosamine-toxicated rats. Kutkoside (12 mg/kg/day for 7 days) also protected against changes in most of the hepatic and serum constituents studied.
Picroside II significantly attenuated FFAs-induced lipotoxicity in hepatocyte cell lines. The reduction in ROS, increased antioxidant enzymes, and improvement in mitochondrial function underlie the mechanisms of action of picroside II in this model.
Human/Clinical Evidence
A randomised, double-blind, placebo-controlled trial including patients diagnosed with acute viral hepatitis administered 375 mg of Picrorhiza kurroa root powder three times daily over a two-week period. Bilirubin, serum glutamic-oxaloacetic transaminase (SGOT), and serum glutamic pyruvic transaminase (SGPT) values were significantly lower in the treatment group compared to the placebo group.
Regarding the standardised Picroliv fraction in humans: The data investigating picroliv activity in humans relates to one RCT. A planned trial involving two groups of patients treated with antituberculosis drugs (N = 260), one treated with picroliv and another with placebo, evaluated the number of patients developing hepatotoxicity in each group. The results of this trial were published in abstract form only 11 years after the protocol, and the endpoints published in the protocol and results published in the abstract markedly did not match.
Evidence strength summary (Hepatoprotection): The overall clinical evidence in humans remains limited in quantity and quality. While one small double-blind placebo-controlled trial in acute viral hepatitis showed statistically significant improvements in liver enzyme and bilirubin markers, scientific consensus on its effectiveness remains limited, with many studies lacking the rigorous design necessary for reliable conclusions. The animal and in vitro evidence base is considerably more robust, with multiple mechanistic studies across diverse hepatotoxicity models. Further well-designed, adequately powered human RCTs are needed.
5.2 Non-Alcoholic Fatty Liver Disease (NAFLD)
Accumulation of free fatty acids (FFAs) in hepatocytes is a hallmark of liver dysfunction and NAFLD. Excessive deposition of FFAs alters lipid metabolism pathways, increasing oxidative stress and mitochondrial dysfunction. Attenuating hepatic lipid accumulation, oxidative stress, and improving mitochondrial function represent potential targets in preventing progression of non-alcoholic fatty liver to non-alcoholic steatohepatitis. Earlier studies with Picrorhiza kurroa extract have shown reduction in hepatic damage and fatty acid infiltration in several experimental models, and also clinically in viral hepatitis.
These findings suggest a need to develop an investigational drug profile of picroside II for NAFLD as a therapeutic strategy, potentially evaluated through the fast-track path of reverse pharmacology.
Evidence strength (NAFLD): Currently preliminary, based on cell culture (HepG2) and animal model data. There are no published human clinical trials in NAFLD specifically.
5.3 Cerebral Ischemia and Neuroprotection
Picroside II has been the subject of a substantial body of preclinical investigation in rodent models of cerebral ischemia/reperfusion injury (CIRI). The best therapeutic dose and time window established in animal studies was injection of picroside II at a dose of 10–20 mg/kg body weight following cerebral ischemia by 1.5–2.0 hours.
In one study using the middle cerebral artery occlusion (MCAO) model: 100 Wistar rats were administered an intraperitoneal injection of picroside II (20 mg/kg). The neurobehavioral function of rats was evaluated using a modified neurological severity score (mNSS) test, and cerebral infarct volume was measured using tetrazolium chloride staining. In the treatment group, neurological function was improved, cerebral infarct volume decreased, neuronal damage in the cortex was attenuated, and the number of apoptotic cells and the pERK1/2 expression significantly decreased compared with the model group.
In a study of anti-inflammation in cerebral ischaemia: Middle cerebral artery occlusion reperfusion models were established in 90 adult healthy female Wistar rats. Picroside II was injected from the tail vein at a dosage of 10 mg/kg. Compared with the ischaemia control group, the neurobehavioral scores, infarction volumes, apoptotic cells, and expressions and concentrations of TLR4, NF-κB, and TNF-α in brain tissue were obviously decreased in the picroside II treatment group.
Myelin nerve fibres arranged in order, vacuolar cells decreased, and the expression of MBP (myelin basic protein) and transcription levels of MBP mRNA increased at different degrees after picroside II treatment, further proving the neuroprotective effect of picroside II against cerebral ischemic injury from various aspects.
Numerous studies have shown that picroside II has promising therapeutic potential for CIRI, which is of great significance for the further development of new clinical drugs.
Evidence strength (Neuroprotection): All evidence is from animal (rodent) models or cell-culture studies. There are no published human clinical trials for stroke or cerebral ischemia. The evidence base is mechanistically coherent and quantitatively substantial, but clinical translation has not yet been established.
5.4 Respiratory Conditions and Allergic Asthma
Picrorhiza kurroa is valued for its anti-malarial, anti-inflammatory, antioxidant, anti-bacterial, and immune modulatory properties attributed to the presence of iridoid glycosides. Traditional Ayurvedic use in asthma and febrile respiratory illness has stimulated laboratory investigation.
In a preclinical study in house-dust mite (HDM)-induced allergic asthma in mice: Picroside II significantly reduced inflammatory cell counts in the bronchoalveolar lavage fluid, the levels of total IgE and HDM-specific IgE and IgG1 in serum, airway inflammation, and mucus hypersecretion in the lung tissues.
Research on steroid-resistant lung inflammation showed that picroside II negatively modulates the SAA-IL-33 axis implicated in steroid-resistant lung inflammation, providing valuable information for the development of picroside II as an alternative therapeutic agent against steroid-refractory lung inflammation in COPD.
Evidence strength (Respiratory): Exclusively preclinical. No human trials for asthma or COPD have been reported in the identified literature.
5.5 Severe Acute Pancreatitis
The effects of picroside II on severe acute pancreatitis (SAP) induced by cerulein were investigated. SAP rats were treated with picroside II (25 mg/kg). The severity of SAP was evaluated by biochemical and histological analyses. Picroside II was found to ameliorate SAP by improving antioxidant and anti-inflammatory activities via NF-κB-dependent autophagy.
Picroside II treatment repaired hepatocellular injury in the SAP model by reducing the activities of AMY, ALT, and AST; reducing the levels of MDA, TNF-α, IL-1, IL-6, p-JAK2, p-STAT3, BAX, and cleaved caspase 3; and increasing the levels of SOD and IL-10.
Evidence strength (Pancreatitis): Animal model data only. No human trials identified.
5.6 Immunomodulation and Vitiligo
A 95% ethanolic extract of roots and leaves of P. kurroa has been shown to enhance the cell-mediated and humoral immune responses to sheep erythrocytes and the phagocytic function of the reticuloendothelial system. P. kurroa was also found effective in vitiligo patients, though the evidence supporting this application in humans is based on older, limited-quality data. Picroliv has also shown anti-viral and immune-stimulant activities and is devoid of any significant CNS, CVS, autonomic, or other systemic activity in preclinical assessments.
Evidence strength (Immunomodulation/Vitiligo): Weak and largely based on older studies and preclinical data. No high-quality modern RCTs in vitiligo or autoimmune conditions have been identified.
5.7 Hepatocellular Carcinoma (Preliminary)
Picroside II is one of the key active components being investigated for hepatocellular carcinoma (HCC). Network pharmacology analysis identified 94 genes as possible targets for picroside II in treating HCC, with GPI, LGALS3, SRC, HRAS, HSP90AA1, MMP9, PPARG, SERPINE1, and VEGFA as the most promising candidates. In vitro studies revealed that picroside II could suppress HepG2 cell migration. It has been demonstrated that picroside II can stop tumors from migrating by attaching to the glycolytic protein GPI and suppressing the downstream glycolytic pathway proteins ALDOA and GAPDH.
Picrosides are known for their hepatoprotective, anti-inflammatory, anti-asthmatic, and anticancer activity, and studies have proposed different anti-cancer activity of picrosides at different concentrations.
Evidence strength (Anticancer): Very preliminary. All evidence is from cell-line studies and network pharmacology modelling. No animal efficacy data or human trial data have been identified for cancer indications.
6. Body Systems and Health Areas Associated with Picrosides
- Hepatic / Gastrointestinal: Hepatoprotection, cholestasis, NAFLD, viral hepatitis, digestion, laxative effect — the primary and most evidence-supported area.
- Neurological: Cerebral ischemia/reperfusion injury, blood-brain barrier protection, anti-apoptotic neuroprotection.
- Immunological / Allergic: Immunomodulation, Th1/Th2 balance, anti-allergic properties, inhibition of histamine release.
- Pulmonary / Respiratory: Asthma (anti-Th2 cytokine), steroid-resistant COPD-related inflammation, traditional use for upper respiratory ailments.
- Pancreatic: Attenuation of severe acute pancreatitis and associated hepatocellular injury.
- Cardiovascular: Preclinical evidence for cardioprotection via antioxidant and anti-apoptotic mechanisms in cardiomyocytes.
- Dermatological: Traditional use and limited clinical reports in vitiligo.
- Oncological (preliminary): In vitro anti-HCC and anti-migration activity.
7. Dosage Forms and Dosages Reported in Studies
The following dosages are reported strictly as described in the identified sources. They reflect research and traditional use doses, not recommendations.
7.1 Traditional/Ayurvedic
- A typical recommended dose of powdered picrorhiza ranges from 400 to 1,500 mg daily, or an equivalent amount in extract form.
7.2 Human Clinical Studies
- In the randomised double-blind placebo-controlled trial in acute viral hepatitis, patients received 375 mg of Picrorhiza kurroa root powder administered three times daily over a two-week period.
7.3 Animal Studies (Picroliv / Standardised Fraction)
- Picroliv was administered orally at 12 mg/kg/day for 7 days in a galactosamine-toxicated rat model.
- Picroside II was administered at 25 mg/kg in a rat severe acute pancreatitis model.
- The best therapeutic dose established in animal studies for neuroprotection was an injection of picroside II at 10–20 mg/kg body weight following cerebral ischemia by 1.5–2.0 hours.
- Picroside II was administered at 10 mg/kg intravenously (tail vein injection) in a cerebral ischemia/reperfusion rat model.
- A dose of 20 mg/kg was administered intraperitoneally in the MCAO cerebral ischemia rat model.
- 20 mg/kg picroside II was reported to restore neural function and provide neuroprotection in brain-injured mice.
Note: Animal and in vitro doses cannot be directly extrapolated to human equivalents. The only identified human oral dose from a controlled clinical trial is the 375 mg three-times-daily (1,125 mg/day) total of crude root powder.
8. Safety Considerations and Drug Interactions
8.1 Acute and Short-Term Toxicity
In acute toxicity studies, picroside II has shown excellent short-term safety in multiple standardised preclinical models. In a 6-hour acute toxicity test in mice, oral administration of picroside II did not induce obvious toxic reactions, abnormal behavioral changes, organic damage, or animal death, with no significant abnormalities detected in hematological and serum biochemical indices. This suggests picroside II has a high degree of safety for short-term use.
Picrorhiza kurroa appears to be relatively safe based on its long history of traditional use. Picroliv is devoid of any significant CNS, CVS, autonomic, or other systemic activity based on preclinical assessments.
8.2 Conservation Status and Material Purity Concerns
The species has become endangered to near extinction due to unregulated collection from the wild, slower plant growth, and ecological destruction of natural habitats. This scarcity means that adulteration or substitution in commercial products is a concern, and authentication of plant material by HPLC or other analytical methods is important for ensuring product quality.
8.3 Cytochrome P450 Enzyme Interactions
A pharmacokinetic interaction study identified a potentially important drug interaction pathway: While picroside II had no inhibition on CYP450 enzymes in human and rat microsomes in vitro, it could inhibit CYP2C and induce CYP3A in rats in vivo. This indicates that picroside II could cause herb-drug interactions via cytochrome P450. The CYP2C family includes enzymes responsible for metabolising numerous clinically important drugs (e.g., warfarin via CYP2C9; various proton pump inhibitors and antidepressants via CYP2C19). CYP3A induction could accelerate the clearance of drugs metabolised by CYP3A4, including many immunosuppressants, statins, and antiretrovirals. These findings require confirmation in human pharmacokinetic studies before firm clinical conclusions can be drawn.
The occurrence of adverse reactions and toxicity caused by herb-drug interactions should be given full attention, especially in the case of drugs with narrow therapeutic indices.
8.4 Autoimmune and Immunostimulant Considerations
Given the documented immunomodulatory and immunostimulant properties of picrosides — including enhanced cell-mediated and humoral immune responses — caution may be warranted in individuals receiving immunosuppressive therapy or those with active autoimmune conditions, though direct clinical evidence for this concern has not been established in the identified human-focused literature.
8.5 Reproductive and Pregnancy Safety
No human data on the safety of picrosides in pregnancy or lactation were identified in the searched peer-reviewed literature. Traditional Ayurvedic use of kutki includes cautions, as noted in some reviews. P. kurroa is traditionally recommended in Ayurveda with certain cautions.
8.6 Evidence Quality Caveat
As a candidate anti-inflammatory bioactive compound with clinical transformation potential, comprehensive and systematic safety evaluation is a core prerequisite for the clinical application of picroside II. The toxicological characteristics, dose-dependent safety effects, long-term safety data, and drug interaction characteristics of picroside II require systematic study based on preclinical and subsequent clinical data.
References
Go back